CAMBRIDGE, Mass. — August 26, 2025 — Leads & Copy — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, will participate in upcoming investor conferences. The conferences include Citi’s 2025 Biopharma Back to School Conference on September 2nd in Boston, MA, featuring a fireside chat at 11:15am ET, and the Baird 2025 Global Healthcare Conference on September 9th in New York, NY, for 1×1 investor meetings. A live webcast and archived replay of the Citi fireside chat will be available on the investors section of Vor Bio’s website.
Vor Bio is dedicated to advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to treat autoantibody-driven conditions.
Contact: Carl Mauch, cmauch@vorbio.com; Sarah Spencer, investors@vorbio.com
Source: Vor Bio
